LLY•benzinga•
Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug
Summary
The FDA approved Eli Lilly's Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 22, 2024 by benzinga